Picture Kentro Design Is Key to Your Success Berlin 650x100px

Organisation › Details

TME Pharma AG

https://www.tmepharma.com

LinkedIn: https://www.linkedin.com/company/tme-pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial is in discussion with regulatory authorities in the United States and Europe. The company’s second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development. *

	Start	2022-07-15 renamed
	Group	TME Pharma (Group)
	Predecessor	Noxxon Pharma AG
	Industry	drug development technology
	Industry 2	Spiegelmer® technology
	Person	Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev)
	Person 2	Buchanan, Iain (Noxxon 201009– interim CEO before Novexel CEO before Vertex Pharmaceuticals)

	Region	Berlin
	Country	Germany
	Street	8-10 Max-Dohrn-Str.
	City	10589 Berlin
	Tel	+49-30-726247-0
		Address record changed: 2024-01-05

Basic data	Employees	C: 51 to 100 (2011-09-06)
	Currency	EUR
	Cash	1,800,000 (2016-06-30)

		* Document for »About Section«: Apogee Therapeutics, LLC. (12/7/22). "Press Release: Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders". San Francisco, CA.

		Record changed: 2023-12-30